Search results
Results from the WOW.Com Content Network
A large-scale study in Buenos Aires from December 29, 2020, to May 15, 2021, with 663,602 participants aged 60 and older who received Spunik V, the Oxford–AstraZeneca vaccine, or the Sinopharm BIBP vaccine observed an overall efficacy of 98% (95% CI, 95 – 99%) against COVID-19-related deaths. The study noted that the three vaccines showed a ...
The study found that in a sample size of 2,000 the AZD1222 vaccine afforded only "minimal protection" in all but the most severe cases of COVID-19. [468] On 7 February 2021, the Minister for Health for South Africa suspended the planned deployment of about a million doses of the vaccine whilst they examine the data and await advice on how to ...
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
On 29 June 2021, the director of the Gamaleya Institute, Denis Logunov, said that Sputnik V is about 90% effective against the Delta variant. [81] On July 21, researchers from PHE published a study finding that the Pfizer vaccine was 93.7% effective against symptomatic disease from Delta after 2 doses, while the Astrazeneca vaccine was 67% ...
(Reuters) -Moderna said on Thursday its next-generation COVID-19 vaccine candidate showed it was not inferior in efficacy compared to its approved shot in a late-stage study. The experimental ...
Influenza Vaccine. Vaccine efficacy or vaccine effectiveness is the percentage reduction of disease cases in a vaccinated group of people compared to an unvaccinated group.For example, a vaccine efficacy or effectiveness of 80% indicates an 80% decrease in the number of disease cases among a group of vaccinated people compared to a group in which nobody was vaccinated.
Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared ...
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19.